Sitagliptin Phosphate Monohydrate
Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In O♦ctober 2006, Sitagliptin phosphate Januvia was approv$ed by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabete∞s mellitus. The characteristics of this drug are that it can sti£mulate insulin secretion while reducing hunger without causin¶g weight gain. Hypoglycemia and edema will not occβur, and it is suitable for diabetic patients with poor blood glucose control and ¥frequent hypoglycemia.
View details
Chenglian Pharmaceutical is an innovative high-tech p∞harmaceutical enterprise that is market-oriented and realizes ¶industrial development through R&D innovation and technoloγgy transformation.
View details
The non-steroidal anti-inflammatory drug ketoprofen is one of the most important pro✔ducts for the treatment of arthritis. It is well tolerated and has a low incide>nce of side effects
View details
Pranlukast, developed by Ono, is one of the three major leukotriene receαptor antagonists. In clinical application, it has good therapeutic effect on atopic asthma a€nd other types of bronchial asthma, and the market prospect is huge. In the ≈major category of asthma drugs, leukotriene receptor antagonists have the fa★stest growing market share.
View details
Chenglian Pharmaceutical is an innovative high-tech pharmace"utical enterprise that is market-oriented and realizes industr ial development through R&D innovation and technol≈ogy transformation.
View details
Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved★ by FDA for Alzheimer's disease in the United Stγates. Its treatment reaches the target dose and has low toxic and side effects. Itσ has been widely recognized by our medical community, and g≥ood tolerance is its biggest advantage. In October 1999, Donepez±il was launched in China under the trade name "Aricept", which is the main× chemical drug against Alzheimer's disease. At present, CFDσA has approved a number of domestic enterprises to produce donepezil preparations, the mai♣n dosage forms are tablets, capsules, dispersive tablets, oral disintegrating tabl♥ets.
View details
English name Apixaban Trade name ELIQUIS, tablet: Apixab↕an (Eliquis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inh★ibitor, was approved for use in the 27 EU member states. The world'λs first drug approved to prevent venous thromboembolis∞m (VTE) in adult patients undergoing elective hip or knee replacement. εFrom June 2019 to June 2020, the annual sales of apixaban products overseas re≥ached about $15.4 billion, with a year-on-year growth of nearly 32%, and the API ®consumption reached about 23,960 kg, with a year-on-year growth of about 28%. Compaαred with its main competitor, Rivaroxaban, the drug's annual♥ overseas sales are about $4.5 billion higher.
View details
Chenglian Pharmaceutical is an innovative high-tech pharm☆aceutical enterprise that is market-oriented and realizes ind×ustrial development through R&D innovation and technology tr±ansformation.
View details
Follow WeChat
Anhui Union Pharmaceuticals Technology Co., Ltd.
Service line:
+86-21-54285906
E-mail：2880705932@qq.com
Add：4th Floor, Building B3, Creative Industry Park, Hefei, Anhui P. R. China.
Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.
